16 completed, 6 recruiting, 3 withdrawn, 1 not yet recruiting. 27 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 27 | Completed 16, Recruiting 6, Withdrawn 3, Not yet recruiting 1, Terminated 1 |
| Phase 1 | 3 | Completed 2, Recruiting 1 |
Follow Rigel Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Adults Placebo, Fostamatinib - Acute Respiratory Distress Syndrome, ARDS | Phase 2 | Not yet recruiting | Inova Health Care Services | 40 | 2026-11-30 | 2026-10-27 |
| Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax Olutasidenib, Azacitidine (AZA) - IDH1 Mutation, Relapsed / Refractory AML | Phase 2 | Recruiting | Timothy Pardee | 25 | 2026-11-01 | 2026-11-04 |
| Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy Olutasidenib, Venetoclax, Azacitidine - Acute Myeloid Leukemia, IDH1 Mutation | Phase 2 | Recruiting | Justin Watts, MD | 16 | 2026-03-31 | 2026-04-16 |
| Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations Olutasidenib, Cladribine (CLAD), Venetoclax - Targeted Therapy, IDH1-Mutated Malignancies | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 68 | 2025-09-12 | 2026-10-05 |
| Study of Olutasidenib and Temozolomide in HGG Olutasidenib + TMZ - High Grade Glioma, Astrocytoma | Phase 2 | Recruiting | Rigel Pharmaceuticals | 60 | 2025-02-01 | 2026-09-01 |
| A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm Olutasidenib - Chronic Myelomonocytic Leukemia, Advanced Myeloproliferative Neoplasms | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2025-01-28 | 2026-10-05 | |
| A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia. Olutasidenib - Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 15 | 2024-12-10 | 2026-09-11 |
| An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis LY3871801, Placebo - Rheumatoid Arthritis | Phase 2 | Completed | Eli Lilly and Company | 164 | 2023-05-23 | 2026-05-22 |
| Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) R906289 Monosodium (R289 Na) - Low Risk Myelodysplastic Syndromes | Phase 1 / Phase 2 | Recruiting | Rigel Pharmaceuticals | 86 | 2022-09-12 | 2026-11-06 |
| Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa Fostamatinib - Hidradenitis Suppurativa | Phase 2 | Completed | Holdsworth House Medical Practice | 20 | 2021-10-01 | 2023-03-01 |
| Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia Fostamatinib, Ruxolitinib - Myelofibrosis, Thrombocytopenia | Phase 2 | Terminated | Washington University School of Medicine | 3 | 2021-05-03 | 2023-12-15 |
| Inflammatory Signal Inhibitors for COVID-19 (MATIS) Ruxolitinib, Fostamatinib, Standard of care - Coronavirus, Covid19 | Phase 1 / Phase 2 | Completed | Imperial College London | 185 | 2020-10-02 | 2025-11-18 |
| A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA) Fostamatinib 150 mg bid - Warm Antibody Autoimmune Hemolytic Anemia | Phase 2 | Completed | Rigel Pharmaceuticals | 26 | 2016-07-01 | 2021-07-21 |
| Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy Fostamatinib Disodium tablet 100 mg, Fostamatinib Disodium tablet 150 mg - IGA Nephropathy | Phase 2 | Withdrawn | Rigel Pharmaceuticals | 2015-09-01 | 2015-10-23 | |
| Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy Fostamatinib 150 mg, Fostamatinib 100 mg, Placebo - IGA Nephropathy | Phase 2 | Completed | Rigel Pharmaceuticals | 76 | 2014-10-01 | 2019-06-27 |
| Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2) R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, Placebo Ophthalmic Solution - Chronic Graft-versus-host Disease | Phase 2 | Completed | Rigel Pharmaceuticals | 35 | 2014-03-01 | 2016-10-10 |
| To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, Placebo - Keratoconjunctivitis Sicca | Phase 2 | Completed | Rigel Pharmaceuticals | 204 | 2013-07-01 | 2016-10-03 |
| Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions R932333, Placebo - Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic | Phase 2 | Completed | Rigel Pharmaceuticals | 54 | 2012-08-01 | 2016-07-14 |
| A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma Placebo, R940343 1mg, R940343 2mg - Asthma | Phase 2 | Completed | Rigel Pharmaceuticals | 301 | 2012-07-01 | 2016-09-29 |
| Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma Fostamatinib Disodium - T Cell Lymphoma | Phase 2 | Completed | Rigel Pharmaceuticals | 18 | 2009-03-01 | 2016-09-19 |
Showing 20 of 27. Sign in to see all of them.
Arthritis, Rheumatoid (4) · Glomerulonephritis, IGA (2) · Keratoconjunctivitis Sicca (2) · Leukemia, Myeloid, Acute (2) · Leukemia, Myelomonocytic, Chronic (2) · Lupus Erythematosus, Systemic (2) · Lymphoma (2) · Myelodysplastic Syndromes (2) · Asthma (1) · Astrocytoma (1) · Brain Neoplasms (1) · Bronchiolitis Obliterans Syndrome (1) · COVID-19 (1) · Coronavirus Infections (1) · Diffuse Intrinsic Pontine Glioma (1)
fostamatinib (14) · olutasidenib (6) · ruxolitinib (3) · Azacitidine (2) · venetoclax (2) · BID protein, human (1) · Beclomethasone (1) · Cladribine (1) · Cytarabine (1) · R333 (1) · Standard of Care (1) · Temozolomide (1) · gilteritinib (1)
United States (20) · Canada (5) · Germany (4) · United Kingdom (4) · Mexico (3) · Australia (2) · Colombia (2) · France (2) · Poland (2) · Argentina (1) · Austria (1) · Belgium (1) · Bulgaria (1) · Czechia (1) · Hong Kong (1)
Daniel B Magilavy, MD (2) · Daniel Magilavy, MD (2) · Elliott Grossbard, M.D. (2) · Jeffrey Skolnik, MD (2) · Kelly Chien, MD (2) · Amy Zhou, M.D. (1) · Arthur Kavanaugh, M.D. (1) · Christopher S. King, MD, FACP (1) · Courtney DiNardo, MD (1) · Daniel B. Magilavy, MD (1) · Eli Meltzer, M.D. (1) · Elliott Grossbard, MD (1) · Harold Nelson, M.D. (1)
PMID 19096013, PMID 19965662, PMID 20879879, PMID 26032537, PMID 30177021, PMID 33687069, PMID 33845867, PMID 34124781, PMID 35179251, PMID 37522746, PMID 41644167
2008 (1), 2014 (1)